A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Investing.com -- Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

U.S. stock futures fell on Friday following a 25 basis point rate hike by the Bank of Japan. Futures of all four indices declined.

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

NATICK, Mass., January 14, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

Allurion Technologies shares rose after agreeing to a private placement with expected gross proceeds of $2.5 million that will extend its runway through early 2026. The stock was up 13% to $3.37.

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss, the Allurion ...

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, ...